Rapamycin for longevity: what the trials actually show in humans.
The animal data is real. The human trials are smaller, shorter, and far more equivocal than the cultural conversation reflects. PEARL, RAP-PAC, the transplant-cohort data, the immune-function trials — and what the longevity claim is and isn't grounded in.
What rapamycin is, and what mTOR is
Rapamycin (international nonproprietary name: sirolimus) is a macrolide compound isolated from Streptomyces hygroscopicus, originally sampled from soil on Rapa Nui (Easter Island) in 1972. It binds the immunophilin FKBP12, and the resulting complex inhibits the mechanistic target of rapamycin (mTOR) — specifically the mTORC1 complex (mechanistic-target-of-rapamycin complex 1).
mTORC1 is a master regulator of cellular anabolism. When nutrients are abundant, it drives protein synthesis, cell growth, and ribosome biogenesis while suppressing autophagy (the cellular recycling pathway). When nutrients are scarce, mTORC1 activity drops, autophagy increases, and the cell shifts toward catabolic maintenance. The longevity hypothesis rests on the idea that chronic mTORC1 hyperactivation accelerates age-related dysfunction, and that pharmacologically dampening it recapitulates some of the benefits of caloric restriction.
Sirolimus has been FDA-approved since 1999 for prevention of organ transplant rejection. It is used at substantially higher chronic doses in that context than the longevity-adjacent protocols call for. The cumulative human safety dataset is therefore large — but it is large for transplant dosing, not for intermittent low-dose longevity dosing, which is a different question.
The animal data — what it says, what it doesn't
The Interventions Testing Program (ITP) is the NIA-funded multi-site program that tests candidate longevity interventions in genetically heterogeneous mice across three independent sites. Rapamycin is the most consistently positive ITP intervention to date.
Harrison and colleagues reported median lifespan extension of ~9% in male and ~14% in female mice when rapamycin was started at 600 days of age (roughly equivalent to 60 human years) [Harrison 2009]. Subsequent ITP work demonstrated dose-dependent effects, sex-differential responses, and effects starting at later ages [Miller 2014]. The signal has been replicated across multiple independent labs and protocols — rare in the longevity literature.
The honest version of the takeaway: rapamycin extends lifespan in mice with high reproducibility. Translation to humans is not the question the ITP set out to answer. The relevant species gap, mTOR sensitivity differences, and the absence of comparable end-of-life measurement in humans all complicate direct extrapolation. The animal data is the best signal in the longevity literature. It is not by itself a human clinical trial.
The animal evidence for rapamycin is the strongest in the longevity field. The human evidence is among the weakest — and that gap is the entire 2026 conversation.
PEARL: the dedicated human longevity trial
PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) is the first dedicated rapamycin-for-longevity human RCT. It enrolled older adults and randomized them to weekly intermittent rapamycin or placebo for 48 weeks, with outcome measures focused on visceral adipose tissue, lean mass, bone mineral density, blood biomarkers, and functional measures [Mannick 2024 PEARL].
The headline results from the published readout were modest. Some subgroup benefits on lean tissue and pain measures were reported. Mortality is not an endpoint achievable in a 48-week trial, and the sample size was not powered for the canonical aging biomarkers. The cleanest framing is that PEARL demonstrated tolerability of an intermittent low-dose protocol in a non-transplant population, and produced hypothesis-generating signals for specific outcomes. It did not demonstrate longevity benefit, because it was not designed to.
The immune-function trials
The Mannick group at Novartis (later resTORbio) published a series of trials testing mTOR inhibition with everolimus, RTB101, and combinations as a way to improve immune function in older adults — measured by antibody response to influenza vaccination and rate of respiratory tract infections [Mannick 2014] [Mannick 2018].
The 2014 study reported improved vaccination response with everolimus. The 2018 study (a phase 2 trial) reported reduced respiratory tract infections at certain doses. The follow-up phase 3 program (PROTECTOR-1) did not replicate the phase 2 finding on its primary endpoint and resTORbio discontinued the program. The honest summary: the immunosenescence signal is real in the early-phase data, the phase 3 confirmation never arrived, and the interpretation in 2026 is therefore unsettled.
What we know from transplant patients on sirolimus
Sirolimus has been used in transplant medicine for over two decades. The retrospective signal from transplant cohorts is mixed. Some analyses suggest reduced incidence of certain age-associated conditions in long-term sirolimus users versus calcineurin-inhibitor comparators; others do not. The transplant population is a complicated reference cohort — these patients are immunosuppressed, often diabetic, and not directly comparable to healthy adults considering off-label longevity use.
The transplant data is useful for understanding the chronic safety profile of mTOR inhibition. It is not useful for estimating longevity-cohort outcomes in healthy adults on intermittent low doses. The cumulative exposure, indication, and concomitant medication profile are too different.
Side-effect profile, taken seriously
Even at intermittent low doses, rapamycin is not a no-cost intervention. The published side-effect profile, observed in both transplant and off-label cohorts, includes:
- Stomatitis (mouth ulcers) — the most commonly reported off-label adverse effect, dose-related.
- Hyperlipidemia — sirolimus reliably elevates LDL cholesterol and triglycerides. Chronic dosing requires lipid monitoring.
- Glucose intolerance and new-onset diabetes — sustained mTOR inhibition impairs insulin signaling in some contexts. Reports of new-onset diabetes in transplant patients are non-trivial. Off-label cohorts at lower doses report less of this, but the dataset is small.
- Impaired wound healing — particularly relevant peri-surgically.
- Immunosuppression — by mechanism. Whether intermittent low doses produce clinically meaningful immunosuppression is unclear; transplant dosing certainly does.
- Edema — particularly peripheral edema, reported across the literature.
The off-label longevity protocols cited in clinical use are typically 5-8 mg orally once weekly, with a 1-2 week washout between cycles variably included. This dosing is derived from clinician extrapolation, PEARL trial protocol, and pharmacokinetic modeling — not from dose-finding trials in healthy adults. The "right" longevity dose in humans is, as of 2026, not known. Clinical practice has moved ahead of formal evidence here.
A tiered framework
We do not write protocols. We write frameworks that you take to a clinician. With that established:
The animal data is strong; the human longevity data is not. If you are not in an at-risk population for sarcopenia, immunosenescence, or cardiovascular disease, the reasonable position is to wait for the larger human trials currently in development before committing to chronic mTOR inhibition.
If the longevity application interests you, enrolling in a registered trial is the highest-information option. PEARL-2 and related protocols are recruiting. Trial participation delivers monitoring, structured dosing, and contribution to the evidence base that off-label use does not.
Off-label intermittent low-dose use with a clinician who is comfortable in this space is increasingly common. Baseline and quarterly lipids, fasting glucose, HbA1c, and CBC are reasonable. The cost-benefit calculation requires honest reckoning with the side-effect profile and the gap in human longevity evidence.
We will not tell you to source sirolimus from research-chemical sites. We will not tell you to skip the clinician step. We will not tell you that the animal data has been replicated in humans, because it has not — yet. Every framework here assumes a physician relationship and structured monitoring.
References
- Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392-395.
- Miller RA, et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell. 2014;13(3):468-477.
- Mannick JB, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179.
- Mannick JB, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med. 2018;10(449):eaaq1564.
- Mannick JB, et al. PEARL: a randomized controlled trial of intermittent rapamycin in healthy older adults. 2024 (published readout).
- Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168(6):960-976.
- Kennedy BK, Lamming DW. The Mechanistic Target of Rapamycin: The Grand Conducter of Metabolism and Aging. Cell Metab. 2016;23(6):990-1003.
- Lamming DW, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012;335(6076):1638-1643.
- Arriola Apelo SI, et al. Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system. Aging Cell. 2016;15(1):28-38.
- Blagosklonny MV. Rapamycin for longevity: opinion article. Aging. 2019;11(19):8048-8067.